GSK has become the first pharma ... identified a protein in RSV a decade ago that looked like a promising antigen for vaccine development. Both Arexvy and Abrysvo target this PreF protein, as ...

The ACIP has now recommended the use of GSK’s RSV vaccine, Arexvy, and PFE’s RSV vaccine, Abrysvo, in adults aged 50-59 who are at high risk of severe RSV disease. Individuals with underlying ...

has voted to recommend the use of respiratory syncytial virus (RSV) vaccines, including GSK's adjuvanted Arexvy, for use in the adult population between the ages of 50 and 59 who are at higher ...

GSK) are expected to reap benefits as an advisory committee of the CDC on Wednesday voted to expand the use of vaccines against the respiratory syncytial virus (RSV) for a broader population in ...

In addition to the RSV vaccine vote, the committee also recommended use of a new meningococcal vaccine from GSK, a chikungunya ... and vaccine development. Follow her on Mastodon and Bluesky.

GSK (GSK) said it is “pleased” that the Advisory Committee on Immunization Practices voted in favor of recommending the use of RSV vaccines including GSK’s AREXVY in adults aged 50-59 who ...

GSK said in the lawsuit that Pfizer began working on its RSV program around 2013, at least seven years after GSK began developing its shot. Pfizer denied the allegations and argued GSK's patents ...

GSK) on Thursday agreed to end a patent lawsuit over claims that the former’s vaccine, Abrysvo for respiratory syncytial virus (RSV) allegedly violated the British pharma giant’s patent rights ...